Recombinant FIV glycoprotein 160 and P24 gag protein
AssigneeAquila Biopharmaceuticals, Inc.
InventorsEli Young, Deborah Davis, James Storey, Gerald Beltz
Life of this patent
Estimating the term…
Abstract
Feline immunodeficiency virus antigens from gp160 envelope protein, gp120 envelope protein and p24 gag protein, useful for the diagnosis, treatment, and prevention of FIV. The invention may also be used to purify FIV.
Claims18
A substantially pure recombinant FIV 0.4 envelope protein obtained from cells infected with FIV.
A plasmid comprising a DNA sequence coding for a FIV 0.4 envelope protein.
A plasmid comprising a DNA sequence coding for a FIV gp160-containing protein.
A plasmid comprising a DNA sequence coding for the FIV 0.4 envelope protein of Bangstom strain.
A process for the preparation of a pharmaceutical composition useful for inducing the production in a cat of antibodies to FIV, the process comprising admixing an immunologically effective amount of the polypeptide comprising the amino acid sequence of the FIV 0.4 envelope protein together with a pharmacologically acceptable carrier.
Dependencies are inferred from the claim text.